Cargando…

Liraglutide and DPP-4 inhibitors – side effects comparative clinical study

The objective of this study was to monitor the side effects of the GLP-1 receptor agonist liraglutide in comparison to those of DPP-4 inhibitors (sitagliptin and vildagliptin), in order to determine their safety, tolerability and therapeutic efficiency. The study was carried out in the “Heart and Di...

Descripción completa

Detalles Bibliográficos
Autores principales:	TIMOFTE, LUMINIŢA, STRATMANN, BERND, QUESTER, WULF, BOJIŢĂ, MARIUS TRAIAN, TSCHOEPE, DIETHELM
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Iuliu Hatieganu University of Medicine and Pharmacy 2013
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4462430/ https://www.ncbi.nlm.nih.gov/pubmed/26527929

Ejemplares similares

Heart in Diabetes: Not Only a Macrovascular Disease
por: Stratmann, Bernd, et al.
Publicado: (2011)

Shifting the Disease Management Paradigm From Glucose: What are the pros?
por: Stirban, Alin, et al.
Publicado: (2009)

Peripheral oscillometric arterial performance does not depict coronary status in patients with type 2 diabetes mellitus
por: Jaeger, Magdalene, et al.
Publicado: (2021)

Liraglutide relieves cardiac dilated function than DPP‐4 inhibitors
por: Hiramatsu, Takeyuki, et al.
Publicado: (2018)

Impact of GLO1 Knock Down on GLUT4 Trafficking and Glucose Uptake in L6 Myoblasts
por: Engelbrecht, Britta, et al.
Publicado: (2013)

Chronic Hyperglycaemia Inhibits Tricarboxylic Acid Cycle in Rat Cardiomyoblasts Overexpressing Glucose Transporter Type 4
por: Stratmann, Bernd, et al.
Publicado: (2022)

Intracellular Accumulation of Methylglyoxal by Glyoxalase 1 Knock Down Alters Collagen Homoeostasis in L6 Myoblasts
por: Stratmann, Bernd, et al.
Publicado: (2017)

Clinical Use of DPP-4 Inhibitors
por: Gallwitz, Baptist
Publicado: (2019)

Potentially inappropriate medications in elderly ambulatory and institutionalized patients: an observational study
por: Primejdie, Daniela Petruta, et al.
Publicado: (2016)

Renoprotective Effects of DPP-4 Inhibitors
por: Kawanami, Daiji, et al.
Publicado: (2021)

Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor
por: Wang, Aiying, et al.
Publicado: (2012)

Description of a systematic pharmaceutical care approach intended to increase the appropriateness of medication use by elderly patients
por: PRIMEJDIE, DANIELA PETRUTA, et al.
Publicado: (2014)

Effect of Cold Atmospheric Plasma Therapy vs Standard Therapy Placebo on Wound Healing in Patients With Diabetic Foot Ulcers: A Randomized Clinical Trial
por: Stratmann, Bernd, et al.
Publicado: (2020)

Mosaic vs. Single Image Analysis with Confocal Microscopy of the Corneal Nerve Plexus for Diagnosis of Early Diabetic Peripheral Neuropathy
por: Matuszewska-Iwanicka, Aleksandra, et al.
Publicado: (2022)

Micro–RNA-126 Reduces the Blood Thrombogenicity in Diabetes Mellitus via Targeting of Tissue Factor
por: Witkowski, Marco, et al.
Publicado: (2016)

Metabolomic Signature of Coronary Artery Disease in Type 2 Diabetes Mellitus
por: Stratmann, Bernd, et al.
Publicado: (2017)

The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence
por: Zhang, Tianli, et al.
Publicado: (2021)

Establishment of a selective evaluation method for DPP4 inhibitors based on recombinant human DPP8 and DPP9 proteins
por: Liu, Jinglong, et al.
Publicado: (2014)

MicroRNA-19a contributes to the epigenetic regulation of tissue factor in diabetes
por: Witkowski, Marco, et al.
Publicado: (2018)

Metformin Is Associated with Reduced Tissue Factor Procoagulant Activity in Patients with Poorly Controlled Diabetes
por: Witkowski, Marco, et al.
Publicado: (2020)

Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

Dysregulation of DPP4 Is Associated with the AMPK/JAK2/STAT3 Pathway in Adipocytes Under Insulin Resistance Status and Liraglutide Intervention
por: Cheng, Fangxiao, et al.
Publicado: (2019)

Acute myocardial infarction associated to DPP-4 inhibitors
por: Nunes, J P L, et al.
Publicado: (2014)

Use of DPP-4 inhibitors in patients with COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2020)

PLA1A2 platelet polymorphism predicts mortality in prediabetic subjects of the population based KORA S4-Cohort
por: Stratmann, Bernd, et al.
Publicado: (2014)

Weight neutrality with the DPP-4 inhibitor, vildagliptin: Mechanistic basis and clinical experience
por: Foley, James E, et al.
Publicado: (2010)

Randomized clinical trial comparing the efficacy and safety of treatment with the once‐weekly dipeptidyl peptidase‐4 (DPP‐4) inhibitor omarigliptin or the once‐daily DPP‐4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy
por: Goldenberg, Ronald, et al.
Publicado: (2017)

Coadministration of DPP-4 inhibitor and insulin therapy does not further reduce the risk of cardiovascular events compared with DPP-4 inhibitor therapy in diabetic foot patients: a nationwide population-based study
por: Lin, Yi-Hsuan, et al.
Publicado: (2018)

DPP4 in Diabetes
por: Röhrborn, Diana, et al.
Publicado: (2015)

Side Effects Associated with Liraglutide Treatment for Obesity as Well as Diabetes
por: Seo, Young-Gyun
Publicado: (2021)

Alogliptin: a new addition to the class of DPP-4 inhibitors
por: Andukuri, Radha, et al.
Publicado: (2009)

Renal Effects of DPP-4 Inhibitors: A Focus on Microalbuminuria
por: Haluzík, Martin, et al.
Publicado: (2013)

Pleiotropic Benefits of DPP-4 Inhibitors Beyond Glycemic Control
por: Kang, Seon Mee, et al.
Publicado: (2021)

Effects of DPP‐4 inhibitor linagliptin and GLP‐1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: A randomized, open‐label, 2‐arm parallel comparative, exploratory trial
por: Yabe, Daisuke, et al.
Publicado: (2016)

DPP-4 Inhibition and the Path to Clinical Proof
por: Ahrén, Bo
Publicado: (2019)

Clinical trial simulation methods for estimating the impact of DPP-4 inhibitors on cardiovascular disease
por: Schuetz, Charles Andy, et al.
Publicado: (2015)

Cost and clinical impact of a nonmedical DPP-4 inhibitor switch in patients with diabetes
por: Kheloussi, Steven, et al.
Publicado: (2021)

A comparative study of the binding properties, dipeptidyl peptidase‐4 (DPP‐4) inhibitory activity and glucose‐lowering efficacy of the DPP‐4 inhibitors alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin in mice
por: Berger, Joel P., et al.
Publicado: (2017)

The cost‐effectiveness of dapagliflozin compared to DPP‐4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands
por: Van der Linden, N., et al.
Publicado: (2020)

Drosophila as a Rapid Screening Model to Evaluate the Hypoglycemic Effects of Dipeptidyl Peptidase 4 (DPP4) Inhibitors: High Evolutionary Conservation of DPP4
por: Lagunas-Rangel, Francisco Alejandro, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4agv5ffk45dkonu36a4gagi7ee